Table 1.
Baseline demographic and clinical data for patients with rheumatoid arthritis included in a study investigating serological markers associated with disease activity during treatment with rituximab, and healthy control subjects.
| Characteristic | Rheumatoid arthritis group n = 35 | Control group n = 30 |
|---|---|---|
| Sex, male/female | 6/29 | 5/25 |
| Age, years | 58.3 ± 13.5 | 50.0 ± 10.3 |
| Disease duration, years | 13.6 ± 6.8 | NA |
| DAS28 | 5.4 ± 1.6 | NA |
| RF positive | 21 (60) | NA |
| ACPA positive | 20 (57) | NA |
| C3, mg/dl | 128.7 ± 21.3 a | 110.0 ± 25.0 |
| C4, mg/dl | 29.7 ± 10.2 b | 22.7 ± 8.3 |
| Concomitant treatment | ||
| csDMARDs | 26 (74.3) | NA |
| Prednisone | 28 (80.0) | NA |
Data presented as mean ± SD or n (%).
NA, not applicable; DAS28, 28-joint disease activity score; RF, rheumatoid factor; ACPA, anticitrullinated protein antibody; C3, complement 3; C4, complement 4; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs.
a
P = 0.01 and bP = 0.03 versus control group; Mann–Whitney U-test.